RxDoctor Payments Data

Dino Klisovic, MD

Retina Specialist · Dublin, OHNPI 1477644573

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $17,476 of the $20,987 with a category attached, or 83.3%. US Retina LLC accounts for 83.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $7,693 and has fallen 85.5% since, to $1,113 in 2025.

$20,987in general payments, 2019–2025

Across 173 payments — averaging $121.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$17K
  • Mallinckrodt Hospital Products Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$722
  • Genentech USA, Inc.$489
  • Alimera Sciences, Inc.$292
  • Apellis Pharmaceuticals, Inc.$226
  • plus $778 from 12 others

What the payments were for

  • Food & beverage$3,41216%
  • Education$990%
  • Ownership interest$17,47683%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,987 in reported general payments places this provider in the 75th percentile of 69 retina specialist providers in Ohio.

See all retina specialist providers in Ohio

Medicare billing

Part B allowed, 2024
$1,961,832
Medicare patients
668
Services billed
20,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin24$2,107,710
LeukeranChlorambucil12$1,069,906
Humira(Cf) PenAdalimumab22$217,948
Mycophenolate Mofetil209$21,705
RestasisCyclosporine11$13,579
ValacyclovirValacyclovir Hcl192$9,969
Cyclosporine ModifiedCyclosporine, Modified24$5,442
Prednisolone Acetate117$3,332
Atropine Sulfate110$3,201
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha199$2,318
Timolol Maleate320$2,296
Latanoprost169$1,307
Brimonidine Tartrate131$1,290
Doxycycline Hyclate42$1,246
Azathioprine40$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$1,004$2,107,71024 claims
AbbVieRestasis$209$13,57911 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$74$92116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 69 retina specialist providers in Ohio.

Other retina specialist in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →